How TP53 Controls the DNA Damage Response — and Why Its Loss Drives Therapy Resistance
TP53 is the most frequently mutated gene in human cancer — altered in over 50% of all tumour types — because it sits at the apex of the DNA damage response signalling pathway. When genomic stress is detected, the ATM kinase phosphorylates and stabilises p53, which then executes a transcriptional programme that drives cell cycle arrest, DNA repair, and apoptosis. TP53 mutation does not merely remove this tumour suppressive brake — it actively creates chemotherapy resistance by eliminating the ATM→p53→BAX/PUMA apoptotic cascade that cytotoxic drugs depend on to kill cancer cells, while gain-of-function mutant p53 acquires new oncogenic activities that further accelerate tumour progression.
Quick Answer
TP53 is the most frequently mutated gene in human cancer — altered in over 50% of all tumour types — because it sits at the apex of the DNA damage response signalling pathway. When genomic stress is detected, the ATM kinase phosphorylates and stabilises p53, which then executes a transcriptional programme that drives cell cycle arrest, DNA repair, and apoptosis. TP53 mutation does not merely remove this tumour suppressive brake — it actively creates chemotherapy resistance by eliminating the ATM→p53→BAX/PUMA apoptotic cascade that cytotoxic drugs depend on to kill cancer cells, while gain-of-function mutant p53 acquires new oncogenic activities that further accelerate tumour progression.
The ATM–p53 DNA Damage Sensing Cascade
When a DNA double-strand break occurs — from ionising radiation, replication fork collapse, or genotoxic chemotherapy — ATM is recruited to the break site by the MRN complex (MRE11–RAD50–NBS1) and activated within seconds. ATM then phosphorylates p53 at Ser15, simultaneously phosphorylating MDM2 at Ser395, disrupting the MDM2–p53 interaction and preventing p53 ubiquitination and proteasomal degradation. CHK2, a second ATM substrate phosphorylated at Thr68, provides signal amplification by directly phosphorylating p53 at Ser20 — further blocking MDM2 binding. Within 30 minutes of DNA damage, p53 protein accumulates to levels 10–20-fold above baseline.
This ATM→CHK2→p53 signalling cascade is the canonical DNA damage response pathway and the molecular foundation of TP53 tumour suppression. Under normal conditions, continuous MDM2-mediated ubiquitination keeps p53 at low basal levels with a half-life of ~20 minutes. DNA damage shifts this equilibrium decisively: ATM-phosphorylated p53 (Ser15/Ser20) can no longer be efficiently ubiquitinated by MDM2, while ATM-phosphorylated MDM2 (Ser395) cannot efficiently ubiquitinate p53 — a double block that ensures rapid p53 accumulation. TP53 mutations disrupt the output end of this cascade: ATM detects damage and phosphorylates the mutant p53 protein, but mutant p53 cannot bind DNA response elements and cannot activate the downstream apoptotic or arrest programmes.
The MDM2–p53 Autoregulatory Feedback Loop
MDM2 is the primary negative regulator of p53, operating through a tightly autoregulated feedback circuit. MDM2 directly binds p53's transactivation domain (residues 18–26), blocking co-activator interaction and driving polyubiquitination at p53 C-terminal lysines for proteasomal degradation. p53 transcriptionally activates MDM2 from its P2 promoter — which contains two p53 response elements — creating a negative feedback loop that normally limits p53 activity to stress conditions and terminates the damage response once repair is complete.
CDKN2A encodes p14ARF, which sequesters MDM2 in the nucleolus and blocks MDM2-mediated p53 ubiquitination, amplifying p53 activity during oncogene-induced stress. This explains why CDKN2A deletion simultaneously disables both the pRb pathway (through p16INK4a loss) and the p53 pathway (through ARF loss). In tumours retaining wild-type TP53, MDM2 amplification — present in ~10% of liposarcomas and various sarcoma subtypes — effectively phenocopies TP53 mutation by constitutively suppressing wild-type p53 signalling.
The p53 Transcriptional Programme: Cell Cycle Arrest and Apoptosis Execution
Stabilised p53 tetramerises and binds p53 response elements (RRRCWWGYYY half-sites) in promoters of hundreds of target genes, executing a context-dependent transcriptional programme. At G1/S, p53 activates CDKN1A (encoding p21), which binds and inactivates CDK2–cyclin E and CDK4–cyclin D complexes, enforcing G1 arrest. p53 also activates GADD45A for G2/M arrest, creating simultaneous checkpoint engagement at multiple cell cycle phases.
When DNA damage is irreparable, p53 switches from transient arrest to permanent cell elimination through the intrinsic apoptosis pathway. The p53 apoptotic programme requires transcription of BAX (a pro-apoptotic BCL2 family member that oligomerises to form mitochondrial pores), PUMA (a BH3-only protein that neutralises BCL2, BCL-XL, and MCL1), and NOXA (which specifically antagonises MCL1). Together, these transcriptional targets shift the BCL2 family balance toward mitochondrial outer membrane permeabilisation (MOMP), cytochrome c release, and caspase cascade activation. The ATM→p53→PUMA/BAX→MOMP signalling axis is the core mechanism by which DNA-damaging chemotherapy kills cancer cells — and the axis that TP53 mutations abolish.
How TP53 Mutations Disable DNA Damage Signalling
Unlike most tumour suppressors where inactivation occurs through truncating deletions or nonsense mutations, approximately 75% of cancer-associated TP53 mutations are missense mutations at the DNA-binding surface — hotspot residues R175, G245, R248, R249, R273, and R282. These mutations operate through three mechanistically distinct modes. First, loss of function: the mutant protein cannot bind p53 response elements and cannot activate CDKN1A, BAX, or PUMA transcription — the cell retains ATM activity and phosphorylates the mutant p53 protein, but cannot transduce this into downstream checkpoint or apoptotic execution. Second, dominant-negative effect: mutant p53 tetramerises with wild-type p53 from the remaining allele, poisoning the complex — a mechanism explaining why heterozygous TP53 mutations in Li-Fraumeni syndrome confer extraordinarily high cancer penetrance despite theoretical retention of one wild-type allele. Third, gain-of-function.
The dominant-negative mechanism has a critical clinical implication: missense TP53 mutations are more oncogenic than truncating mutations precisely because the full-length misfolded protein accumulates (no MDM2-binding means no ubiquitination) and poisons remaining wild-type p53 function. This also means immunohistochemistry for p53 shows strong diffuse nuclear staining in missense-mutant tumours (protein accumulation) but complete absence of staining in truncating mutations — a diagnostic pattern exploited in surgical pathology.
Gain-of-Function Mutations: How Mutant p53 Becomes an Active Oncogene
Gain-of-function (GOF) TP53 mutations — particularly R175H, R248W, and R273H — produce mutant p53 proteins that actively promote tumourigenesis beyond simply losing tumour suppression. GOF mutant p53 binds and inactivates p63 and p73 (p53 family members that retain partial tumour suppressive function in p53-null cells), promoting invasion and metastasis through integrin recycling pathways. GOF mutant p53 also binds transcriptional co-activators to amplify MYC-driven transcription and cooperates with KRAS oncogenic signalling to enhance invasion and metabolic reprogramming through the mevalonate pathway.
In mouse models, knock-in of p53 R175H or R248W produces a dramatically different tumour spectrum with earlier onset than p53 null — confirming that GOF mutations are actively oncogenic, not merely loss-of-function. These data rationalise p53 reactivation strategies: APR-246 (eprenetapopt) alkylates cysteine residues in the p53 core domain to restore wild-type conformation in specific GOF mutants. The allosteric mechanism is mutation-specific — APR-246 is most effective at R175H and C242S mutants — motivating mutation-stratified selection for clinical trials in TP53-mutant AML and MDS.
Why TP53 Mutations Drive Chemotherapy and Radiotherapy Resistance
Wild-type p53 is the critical transducer of genotoxic stress into apoptotic execution. Anthracyclines, platinum compounds, taxanes, and topoisomerase inhibitors all generate DNA damage or replication stress that activates ATM, which stabilises p53 to activate the BAX/PUMA→MOMP→caspase apoptosis cascade. TP53-mutant cancer cells sense the same DNA damage through ATM but cannot transduce this signal into apoptotic execution — creating fundamental resistance to the killing mechanism of chemotherapy.
This resistance is compounded by GOF p53 activities: mutant p53 binds and inactivates p73, which can partially substitute for p53 in apoptosis induction. By eliminating both p53 and p73-mediated apoptosis, GOF mutations create near-complete resistance to genotoxic chemotherapy. Importantly, TP53 loss also removes the G1/S checkpoint — forcing cells to rely on G2/M arrest for DNA damage responses. This creates a therapeutic vulnerability: WEE1 inhibitors (adavosertib) and CHK1 inhibitors abrogate the G2/M checkpoint, forcing premature mitotic entry with unrepaired DNA. This G2/M checkpoint abrogation is selectively lethal in TP53-null tumours that lack the backup G1 arrest mechanism, representing the most clinically validated synthetic lethality approach for TP53-mutant cancer.
Restoring p53 Signalling: MDM2 Inhibitors and BH3 Mimetics
Two complementary therapeutic strategies target the p53 pathway. For TP53-wild-type tumours suppressed by MDM2 overexpression or amplification, MDM2 inhibitors (idasanutlin, navtemadlin, milademetan) restore ATM→p53 signalling by occupying p53's hydrophobic binding cleft on MDM2, re-establishing p53 downstream transcriptional activation of CDKN1A-driven arrest and BAX/PUMA-driven apoptosis. Clinical responses have been demonstrated in MDM2-amplified liposarcoma and TP53-wild-type AML.
For TP53-mutant tumours, a parallel strategy bypasses the disabled p53 pathway by targeting the downstream apoptosis machinery directly. BH3 mimetics such as venetoclax (BCL2 inhibitor) force mitochondrial outer membrane permeabilisation independent of the p53→BAX/PUMA axis, exploiting high BCL2 priming in haematological malignancies. This approach is clinically validated in CLL and AML, where venetoclax achieves deep responses regardless of TP53 mutation status — demonstrating that bypassing the disabled ATM→p53→apoptosis cascade is a tractable alternative to restoring it.
References
This article is based on peer-reviewed scientific literature including PubMed, UniProt, The Cancer Genome Atlas (TCGA), and published clinical trial data. For medical decisions, consult a qualified healthcare professional.